(DFRA) TrimTabs Trust - Donoghue - Ratings and Ratios
Exchange: BATS • Country: USA • Currency: USD • Type: Etf • ISIN: (N/A)
DFRA: Real Asset, Equities, Large-Cap, Value, Infrastructure
The Donoghue Forlines Yield Enhanced Real Asset ETF (BATS:DFRA) is an exchange-traded fund that employs a rules-based strategy to provide investors with exposure to real assets equities. The fund is managed by FCF Advisors LLC, and its underlying index is sponsored and maintained by FCF Indexes LLC, an affiliate of the investment adviser.
The funds investment objective is achieved by investing at least 80% of its net assets in component securities of the underlying index under normal market circumstances. The underlying index is designed based on proprietary research conducted by the adviser, aiming to track the investment results of the selected real assets equities.
From a technical standpoint, the ETFs price action indicates a potential bullish trend. With the short-term Simple Moving Averages (SMA20 and SMA50) below the current price, and the long-term SMA200 being closely approached, the ETF is showing signs of stability and potential for growth. The Average True Range (ATR) of 0.54, representing a 1.89% daily volatility, suggests that the ETF is experiencing moderate price fluctuations.
Considering the current price of $28.67 and the 52-week high and low of $30.42 and $24.56, respectively, the ETF appears to be trading near its long-term SMA200. With the Assets Under Management (AUM) standing at $52.20M USD, the fund has a relatively modest size, which could impact its liquidity and trading dynamics.
Forecasting the ETFs future performance, we can expect a potential breakout or consolidation around the current price level. If the SMA20 and SMA50 continue to rise and converge with the current price, it could signal a bullish trend continuation. Conversely, a decline below the SMA50 could indicate a reversal. Given the current technical and fundamental data, a reasonable forecast would be a gradual increase in the ETFs price, potentially reaching $30.00 in the short term, driven by the stability of the real assets equities and the overall market conditions.
Additional Sources for DFRA ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
DFRA ETF Overview
Market Cap in USD | 54m |
Category | Large Value |
TER | 0.69% |
IPO / Inception | 2021-12-13 |
DFRA ETF Ratings
Growth Rating | 40.6 |
Fundamental | - |
Dividend Rating | 84.8 |
Rel. Strength | -5.86 |
Analysts | - |
Fair Price Momentum | 33.53 USD |
Fair Price DCF | - |
DFRA Dividends
Dividend Yield 12m | 8.18% |
Yield on Cost 5y | 11.38% |
Annual Growth 5y | 241.11% |
Payout Consistency | 80.0% |
Payout Ratio | % |
DFRA Growth Ratios
Growth Correlation 3m | 8.4% |
Growth Correlation 12m | -20.7% |
Growth Correlation 5y | 90% |
CAGR 5y | 9.76% |
CAGR/Max DD 5y | 0.49 |
Sharpe Ratio 12m | -0.01 |
Alpha | -6.71 |
Beta | 0.672 |
Volatility | 14.92% |
Current Volume | 6.4k |
Average Volume 20d | 4.7k |
As of June 17, 2025, the stock is trading at USD 28.45 with a total of 6,384 shares traded.
Over the past week, the price has changed by +0.14%, over one month by -0.78%, over three months by -0.74% and over the past year by +4.02%.
Partly, yes. Based on ValueRay´s Analyses, TrimTabs Trust - Donoghue (BATS:DFRA) is currently (June 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 40.58 and therefor an somewhat technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DFRA is around 33.53 USD . This means that DFRA is currently undervalued and has a potential upside of +17.86% (Margin of Safety).
TrimTabs Trust - Donoghue has no consensus analysts rating.
According to our own proprietary Forecast Model, DFRA TrimTabs Trust - Donoghue will be worth about 37.8 in June 2026. The stock is currently trading at 28.45. This means that the stock has a potential upside of +32.76%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 37.8 | 32.8% |